Arzneiwerk VIDA Valuation
Is TLIK undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of TLIK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate TLIK's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate TLIK's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for TLIK?
Key metric: As TLIK is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is TLIK's PS Ratio? | |
|---|---|
| PS Ratio | 0.08x |
| Sales | €59.71m |
| Market Cap | €4.61m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.3x |
| Enterprise Value/EBITDA | -13x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does TLIK's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.1x | ||
HAEK HAEMATO | 0.3x | n/a | €71.1m |
EIF MedNation | 0.1x | n/a | €4.9m |
UOM AS Latvijas Juras medicinas centrs | 0.5x | n/a | €5.4m |
MF6 MagForce | 3.3x | 50.9% | €3.6m |
TLIK Arzneiwerk VIDA | 0.08x | n/a | €4.6m |
Price-To-Sales vs Peers: TLIK is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (0.3x).
Price to Sales Ratio vs Industry
How does TLIK's PS Ratio compare vs other companies in the DE Healthcare Industry?
Price-To-Sales vs Industry: TLIK is good value based on its Price-To-Sales Ratio (0.1x) compared to the European Healthcare industry average (0.6x).
Price to Sales Ratio vs Fair Ratio
What is TLIK's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.08x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate TLIK's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Universal Health Services
US$13.1b
Through its subsidiaries, owns and operates acute care hospitals, and outpatient and behavioral health care facilities.
UHS
US$186.00
7D
-5.6%
1Y
50.0%
Shandong Weigao Group Medical Polymer
HK$20.7b
Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.
UK2
HK$0.53
7D
-6.2%
1Y
-37.3%
CVS Health
US$70.5b
Provides health solutions in the United States.
CVS
US$53.28
7D
3.9%
1Y
-14.3%